Forbion — Full Portfolio

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)James Lillie(Executive Officer)Christopher A Kroeger(Executive Officer, Director)Jonathan Gillis(Executive Officer)

Board seatNanna Luneborg· per SEC Form D · $372.4M raise · filed Jul 2025

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)

Co-investorsMonograph Capital PartnersSofinnova Partners

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plc+4 more

Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD).

BiotechHealthtechSan Francisco, US

Co-investorsNovo HoldingsSofinnova VenturesSanofi Ventures

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsVersant VenturesAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)

Co-investorsNovartis Venture FundSanofi VenturesVersant Ventures

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)Kees Been(Chief Executive Officer)inJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios CapitalNovartis Venture FundSunstone Capital

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

Susan Hill(Founder & Chief Executive Officer)Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsGV (Google Ventures)Johnson & Johnson Innovation – JJDCNorthpond VenturesSV Health Investors

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)Karen Uhlmann(Vice President Operations & IP, Co-Founder)Wolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRemiges Ventures, Inc.Vesalius Biocapital Partners

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsAtlas VentureBiotechnology Value FundLightspeed Venture PartnersResearch Corporation TechnologiesTCG Crossover

BiotechHealthtechCambridge, US

James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)

BoardJoseph Boystak(Director)

Board seatGeert-Jan Mulder· per SEC Form D · $2.2M raise · filed Jul 2015

BiotechStevenage, Hertfordshire

Ian Pitfield(Executive Officer)David Fellows(Director)Jessica Stitt(Executive Officer)Renee Gala(Director)Khurem Farooq(Executive Officer)Edward Lang(Executive Officer)

Board seatWouter Joustra· per SEC Form D · $148M raise · filed Apr 2021

Co-investorsSofinnova Ventures

Privately-held biotech company developing biologic therapies for retinal diseases

BiotechBoston, US

William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)

BoardZach Scheiner(Director)inMegan Krench(Director)

Board seatDmitrij Hristodorov· per SEC Form D

Co-investorsSanofi VenturesAvego BioScience CapitalRA CapitalSamsara BioCapital

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Board seatMarco Boorsma· per SEC Form D · $6.9M raise · filed Jul 2017

Co-investorsPappas Capital

BiotechScotch Plains, US

NAVEEN MANU DARYANI(Executive Officer)STEPHEN BASIL THOMAS(Executive Officer, Director, Promoter)WILLIAM DALEY BONIFICIO(Executive Officer, Promoter)

BoardANDREW LEVIN(Director)

Board seatWouter Joustra· per SEC Form D · $100M raise · filed Sep 2024

Co-investorsRA Capital

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)

Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundGilde Healthcare+1 more

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPebblebedAndera PartnersBGVFountain Healthcare PartnersHTGFPMV+2 more

Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism.

BiotechMedical Devices

Co-investorsBioMedPartnersJeito CapitalSeroba Life SciencesBioGeneration Ventures

Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.

BiotechHealthtechMedical DevicesOss, NL

Co-investorsBOMCurie CapitalNovartis Venture FundPureos BioventuresBioGeneration Ventures

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)

Co-investorsLongwood FundSofinnova VenturesBAM ElevateFinchley Healthcare VenturesLuma GroupNovo Holdings+1 more

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.

BiotechHealthtech

Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova Partners+3 more

Forbion is a global venture capital firm that invests in biotech innovations and sustainable solutions focused on human and planetary health.

BiotechClimate TechImpact & Social Good

Co-investorsBOMKfW Capital

Genomines uses biological systems to extract battery-grade nickel from low-grade soils, producing critical metals at lower cost and environmental impact than traditional mining.

BiotechCleantechEnergyNew MaterialsParis, FR

Fabien Koutchekian(CEO)inDali Rashid(CTO)in

Co-investorsCarbonDeepTech & Climate FondsEntrepreneur FirstLOWERCARBONLowercarbon CapitalSTATION F+4 more

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsNovartis Venture FundSV Health InvestorsDementia Discovery Fund

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess BiotechnologyAtlas VentureNextech InvestRA Capital

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)

Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.

BiotechDeep TechMedical DevicesWatertown, US

Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)

BoardAleks Radovic-Moreno(Director)inDan Janney(Director)

Co-investorsAlta PartnersLongwood FundMission BiocapitalDolby Family VenturesService Provider Capital

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)Geert-Jan Mulder(Director)John Friedman(Director)Harold R. Werner(Director)

Co-investorsEaston CapitalSofinnova VenturesEaston Capital Investment Group

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

Pablo Rojas(Founder)in

Co-investorsNovartis Venture FundY CombinatorGlilot Capital PartnersOmega FundsYK Bioventures

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US

Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more

Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.

BiotechHealthtechMedical Devices

Co-investorsSofinnova PartnersBritish Patient CapitalGilde Healthcare

Tropic is a procurement platform that gives finance and procurement teams pricing intelligence, negotiation playbooks, and expert support to reduce spend on SaaS and AI software.

AI & Machine LearningFintechSaaSNew York City, US

Justin Etkin(Founder)David Campbell(Founder)in

Co-investorsShine Capital

A fully integrated gene therapy company developing innovative therapeutics including vectorized antibodies for CNS and somatic disorders, with focus on muscle diseases.